You are here: Industry Insights > cholesterol drug

News List

Sanofi, Regeneron lose patent dispute with Amgen over cholesterol drug pharmaceutical-technology
February 27, 2019
US District Court for the District of Delaware has upheld Amgen’s patent on cholesterol drug Repatha, rejecting a challenge filed by Sanofi and Regeneron.
AstraZeneca licences Luye Pharma cholesterol drug in China pharmaceutical-technology
January 21, 2019
Luye Pharma has granted AstraZeneca’s Chinese division exclusive rights to promote its cholesterol medicine Xuezhikang Capsules in mainland China.
New Cholesterol Drug, Alirocumab's (Praluent), High Price May Not Be Worth It: Study drugs
January 03, 2019
Despite being slashed by half in recent months, the price tag for advanced cholesterol-fighting drugs is still too high to make them cost-effective, a new analysis has concluded.....
Amgen cuts US price of cholesterol drug by 60% pharmaphorum
December 20, 2018
Amgen is cutting the US price of its cholesterol drug Repatha by 60%, following a similar decision by rivals Sanofi and Regeneron earlier this year.
Amgen cuts price of cholesterol drug Repatha by 60% pharmaceutical-technology
October 29, 2018
Amgen has announced plans to reduce the price of its cholesterol drug Repatha by 60% to $5,850 per year, in an effort to improve affordability through lowering patient copays.
Esperion’s cholesterol drug cuts LDL-C in phase 3 fiercebiotech
August 28, 2018
The study also linked the combination to a reduction in high-sensitivity C-reactive protein.
The top 10 cardiovascular drugs in the world fiercepharma
August 29, 2017
Cardiovascular drugs are tough and expensive to develop, but companies are taking the risk.
Alembic Pharma’s cholesterol drug gets US FDA nod financialexpress
May 16, 2017
Fenofibric acid delayed-release capsules are indicated as an adjunctive therapy to diet to reduce triglyceride in patients with hypertriglyceridemia
FDA green-lights Alembic's cholesterol drug pharmafile
May 15, 2017
Alembic Pharmaceuticals has announced that its fenofibric acid delayed-release capsules have been approved by the FDA for reducing high cholesterol and increasing good cholesterol.